Sun Pharma board to consider INR 15,000 Crore NCD issuance

Fund Raising View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹1779.80

prior close

₹1788.10

announcement price

After-mkt

timing

Nifty 100market-1.8%+0.7% vs market

Pharmaceuticals peers, median of 172sector-2.5%+1.3% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty 100 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.0

15m

-0.1

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1-1.8+0.7-2.5+1.3

Next day

-1.1-0.6-0.5-2.6+1.5

-1.1-1.1+0.0-2.5+1.4

-0.6+0.3-0.9-2.6+1.9

-1.9-0.0-1.8-2.5+0.6

-0.9+1.2-2.1-3.2+2.3

-2.1+0.8-2.9-4.4+2.3

15d

-0.1pendingpending-5.0+4.8

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma's board will meet on 12 October 2026 to consider issuing listed, rated, unsecured, redeemable non-convertible debentures (NCDs) on a private placement basis, in one or more tranches. The aggregate amount will not exceed INR 15,000 Crore. NCDs are debt instruments that pay fixed interest and are repaid at maturity.

Likely market impact

Up to INR 15,000 Crore to be raised via private NCD placement. Debt funding, no equity dilution. Board approval pending on 12 Oct.